Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin
复制标题
DOI：
10.1200/jco.1996.14.2.362
复制
发表时间：
1996-02-01
影响因子：
45.3
通讯作者：
Horowitz, ME
中科院分区：
文献类型：
--
作者：
Wexler, LH;Andrich, MP;Horowitz, ME
Purpose: We conducted an open-label, randomized trial to determine whether ICRF-187 would reduce doxorubicin-induced cardiotoxicity in pediatric sarcoma patients.Methods: Thirty-eight patients were randomized to receive doxorubicin-containing chemotherapy (given as an intravenous bolus) with or without ICRF-187, Resting left ventricular ejection fraction (LVEF) was monitored serially with multigated radionuclide angiography (MUGA) scan, The two groups were compared for incidence and degree of cardiotoxicity, response rates to four cycles of chemotherapy, event-free and overall survival, and incidence and severity of noncardiac toxicities.Results: Eighteen ICRF-187-treated and 15 control patients were assessable for cardiac toxicity, ICRF-187-treated patients were less likely to develop subclinical cardiotoxicity (22% v 67%, P
